Literature DB >> 15213263

Alterations in renal endothelial nitric oxide synthase expression by salt diet in angiotensin type-1a receptor gene knockout mice.

Keiko Sato1, Minoru Kihara, Tatsuo Hashimoto, Kei Matsushita, Yu-Ichi Koide, Koichi Tamura, Nobuhito Hirawa, Yoshiyuki Toya, Akiyoshi Fukamizu, Satoshi Umemura.   

Abstract

The effects of altered dietary salt intake and/or hydralazine-induced hypotension on renal endothelial nitric oxide synthase (eNOS) expression were determined in angiotensin type-1a receptor gene knockout (At1a-/-) and wild-type (At1a+/+) mice. In At1a-/- mice, the levels of renal cortical eNOS mRNA and protein were 5 times and 3.5 times higher, respectively, in the high-salt (4% NaCl) group than in the low-salt group (0.3% NaCl). Systemic BP of the high-salt group (105 +/- 4.4 mmHg) was significantly higher than that of the low-salt group (77.0 +/- 4.7 mmHg). When hydralazine was administered to the mutant mice fed a high-salt diet, BP was reduced to 72.5 +/- 1.3 mmHg, with decreases in the levels of renal eNOS mRNA and protein expression to about half of those found in nontreated group. Consistent with the results for eNOS mRNA and protein expression, nicotinamide adenine dinucleotide phosphate (NADPH) diaphorase activity and eNOS immunoreactivity localized in the endothelium of the renal vasculature changed parallel with the amount of salt intake. In contrast to mutant mice, At1a+/+ mice did not show any changes in renal eNOS expression during the manipulation of salt intake and/or hydralazine-induced hypotension. These results suggest that At1a receptor-mediated inputs play critical roles in maintaining renal vascular eNOS expression and activity during changes in salt-water balance and systemic BP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15213263     DOI: 10.1097/01.asn.0000130922.75125.b8

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  5 in total

1.  Requirement of apelin-apelin receptor system for oxidative stress-linked atherosclerosis.

Authors:  Tatsuo Hashimoto; Minoru Kihara; Nozomi Imai; Shin-Ichiro Yoshida; Hiroaki Shimoyamada; Hiroaki Yasuzaki; Junji Ishida; Yoshiyuki Toya; Yoshihiro Kiuchi; Nobuhito Hirawa; Kouichi Tamura; Takuya Yazawa; Hitoshi Kitamura; Akiyoshi Fukamizu; Satoshi Umemura
Journal:  Am J Pathol       Date:  2007-09-20       Impact factor: 4.307

2.  Renal tubule angiotensin II type 1 receptor-associated protein promotes natriuresis and inhibits salt-sensitive blood pressure elevation.

Authors:  Hiromichi Wakui; Kazushi Uneda; Kouichi Tamura; Masato Ohsawa; Kengo Azushima; Ryu Kobayashi; Kohji Ohki; Toru Dejima; Tomohiko Kanaoka; Yuko Tsurumi-Ikeya; Miyuki Matsuda; Kotaro Haruhara; Akira Nishiyama; Machiko Yabana; Tetsuya Fujikawa; Akio Yamashita; Satoshi Umemura
Journal:  J Am Heart Assoc       Date:  2015-03-19       Impact factor: 5.501

3.  Angiotensin receptor-binding protein ATRAP/Agtrap inhibits metabolic dysfunction with visceral obesity.

Authors:  Akinobu Maeda; Kouichi Tamura; Hiromichi Wakui; Toru Dejima; Masato Ohsawa; Kengo Azushima; Tomohiko Kanaoka; Kazushi Uneda; Miyuki Matsuda; Akio Yamashita; Nobuko Miyazaki; Keisuke Yatsu; Nobuhito Hirawa; Yoshiyuki Toya; Satoshi Umemura
Journal:  J Am Heart Assoc       Date:  2013-07-31       Impact factor: 5.501

Review 4.  Salt restriction in kidney disease--a missed therapeutic opportunity?

Authors:  Eberhard Ritz; Otto Mehls
Journal:  Pediatr Nephrol       Date:  2008-06-06       Impact factor: 3.714

5.  Deletion of the angiotensin II type 1 receptor-associated protein enhances renal sodium reabsorption and exacerbates angiotensin II-mediated hypertension.

Authors:  Masato Ohsawa; Kouichi Tamura; Hiromichi Wakui; Akinobu Maeda; Toru Dejima; Tomohiko Kanaoka; Kengo Azushima; Kazushi Uneda; Yuko Tsurumi-Ikeya; Ryu Kobayashi; Miyuki Matsuda; Shinichi Uchida; Yoshiyuki Toya; Hiroyuki Kobori; Akira Nishiyama; Akio Yamashita; Yoshihiro Ishikawa; Satoshi Umemura
Journal:  Kidney Int       Date:  2014-04-02       Impact factor: 10.612

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.